>>Signaling Pathways>> GPCR/G protein>> EBI2/GPR183>>SAE-14

SAE-14 (Synonyms: GPR183 antagonist-1)

Catalog No.GC65986

SAE-14(화합물 SAE-14)는 IC50 값이 28.5nM인 강력하고 특정한 GPR183 길항제이며, HL-60 세포에서 IC50 값이 50nM 미만인 25-OHC 유도 칼슘 동원을 길항할 수 있습니다. 821d96072c2d58d8970e76f526b0f6b8GPR183 길항제-1은 생쥐에서 이질통을 역전시킬 수 있습니다.821d96072c2d58d8970e76f526b0f6b8

Products are for research use only. Not for human use. We do not sell to patients.

SAE-14 Chemical Structure

Cas No.: 1241280-25-0

Size 가격 재고 수량
10mg
US$387.00
재고 있음
25mg
US$729.00
재고 있음
50mg
US$1,080.00
재고 있음

Tel:(909) 407-4943 Email: sales@glpbio.com

고객 리뷰

Based on customer reviews.

  • GlpBio Citations

    GlpBio Citations
  • Bioactive Compounds Premium Provider

    Bioactive Compounds Premium Provider

Sample solution is provided at 25 µL, 10mM.

Description Chemical Properties Product Documents

IC50: 28.5 nM (GPR183)[1]

SAE-14 (compound SAE-14) is a potent, specific GPR183 antagonist with an IC50 value of 28.5 nM, can antagonize 7α, 25-OHC-induced calcium mobilization with IC50 value below 50 nM in HL-60 cells. GPR183 antagonist-1 can reverse allodynia in mice[1].

SAE-14 (compound SAE-14) can able to antagonize 7α, 25-OHC-induced calcium mobilization with an IC50 value below 50 nM[1].

Cell Viability Assay[1]

Cell Line: The human leukemia (HL)-60 cells
Concentration: 5×of the antagonist
Incubation Time: 15 min
Result: Had GPR183-specific (IC50: 28.5nM) and abolished 7a, 25-OHC-induced calcium mobilization in the HL-60 cells.

SAE-14 (compound SAE-14) (i.th.; 2.9 µM; once) can reverse nerve injury-induced allodynia in mice[1].

Animal Model: Male and female ICR mice[1]
Dosage: 2.9 µM
Administration: intrathecal (i.th.) injections; 2.9 µM; once
Result: Reversed CCI-induced mechanical allodynia in a time-dependent manner.

리뷰

Review for SAE-14

Average Rating: 5 ★★★★★ (Based on Reviews and 30 reference(s) in Google Scholar.)

5 Star
100%
4 Star
0%
3 Star
0%
2 Star
0%
1 Star
0%
Review for SAE-14

GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.

Required fields are marked with *

You may receive emails regarding this submission. Any emails will include the ability to opt-out of future communications.